Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Lanreotide is a long-acting somatostatin analogue with proven antitumor effect against metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors (GEP-NETs). Ga-68-DOTATOC PET/CT is a sensitive imaging technique for NETs by targeting somatostatin receptors.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Kim Y, Yoo C, Ryoo B, Ryu J,
Keywords: neuroendocrine tumor, lanreotide, somatostatin receptor, DOTATOC, positron emission tomography, prognosis,
Introduction: In the phase 3 RADIANT-4 study, everolimus (EVE) improved PFS by 7.1 months (mo) compared to placebo (PBO; P<0.00001) in pts with advanced, progressive, nonfunctional NET of lung or GI tract.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Pommier R
Authors: Pommier R, Strosberg J, Singh S, Wolin E, Yao J,
Keywords: Everolimus, nonfunctional NET, prior chemotherapy,
Introduction: In the phase III RADIANT-3 trial, EV demonstrated a significant improvement in PFS with a median of 11.0 v. 4.6 months (mo) for placebo in pWDNETs pts.
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author: pusceddu s
Authors: Pusceddu S, De Braud F, Milione M, Mazzaferro V, Damato A,
Keywords: everolimus,
#659 Everolimus in Patients with Previously Treated Metastatic Neuroendocrine Tumors (NETs)
Introduction: Everolimus is the standard of care in well-differentiated NETs. Previous randomized trials included patients treated with a maximum of two lines of prior chemotherapy. We evaluated everolimus in heavily pretreated patients with NETs.
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author:
Authors: Gorbunova V, Orel N, Kuzminov A, Markovich A, Odintsova A,
Keywords: neuroendocrine tumor, everolimus,
Introduction: Sorafenib (S) and bevacizumab (B) as single agents have shown efficacy and acceptable toxicity in NETs phase II trials. S+B combination has shown manageable toxicity in phase I trials in solid tumors.
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Castellano D, Capdevila J, Salazar R, Sastre J, Alonso V,
Keywords: targeted therapy, sorafenib, bevacizumab,